TMED5 and neoplasm: First, LA14 alleviated the d-GalN-induced upregulation of 37 hepatic proteins (Fig. 4C), which included tumor-associated biomarkers (TXNRD1, GIT1, TMED5, IMPA2, RBBP7, EMD, NAP1L1, STMN1, ITIH1, FBLIM1, USP9X, EZR, CANT1, STMN2, ROCK2, and COL12A1), immune suppressors (KIF13B, TUBB5, UBE2D3, GBP7, ESAM, PLG, and CASP1), inducers of hepatic injury (KDSR and DEFA5), lipid metabolic proteins (PON3, DHRS7, TMEM62, DDB1, RDH10, LPL, and CYP2D1), antioxidant molecules (CYP2C11 and DNAJC9), and proteins with unknown function (UBXN4, GDPD1, and LOC100361907).